In the non-pivotal, dose-confirmation stage of the randomized Phase 3 PRESERVE-003 trial in metastatic squamous NSCLC after PD-(L)1 therapy...

Topline data: In triple-class–exposed multiple myeloma patients with three prior lines of therapy from CARTITUDE-1, a single infusion of...

Preclinical data presented at ASH showed that Prelude Therapeutics’ JAK2V617F-selective JH2 inhibitor PRT12396 inhibited mutant JAK2 signaling while preserving...

In a 12-week, randomized, double-blind, placebo-controlled study in stable COPD, EP395 (glasmacinal) reduced sputum neutrophilic inflammation versus placebo, was...

In a Phase Ib/II study of 103 patients with myeloid malignancies, lisaftoclax plus azacitidine delivered an overall response rate...

In a registrational Phase II study of 77 patients with BTK inhibitor–refractory relapsed/refractory CLL/SLL, lisaftoclax monotherapy delivered a 62.5%...

Objective response rate of 83% with two complete responses and a median progression-free survival of 22.1 months were reported...

In a humanized high-grade B‑cell lymphoma xenograft model, ARV‑393 combined with glofitamab delivered 81% tumor growth inhibition with concomitant...

In updated Phase 1/2 data from 31 sickle cell disease patients treated with ristoglogene autogetemcel (risto-cel; formerly BEAM-101), mean...

In newly diagnosed AML patients ineligible for induction, tuspetinib plus venetoclax and azacitidine delivered a 90% CR/CRh rate across...